GlobeNewswire·Nov 11, 2026, 5:12 PM ET

Juniper Biosciences Builds Clinical and Commercial Leadership Teams with Appointments of Deepak Behera, M.D., as Chief Medical Officer, Javed Mahmood, Ph.D., as Senior Director of Clinical Development, and Robert Sgroi as Chief Commercial Officer

Juniper Biosciences appointed Deepak Behera, M.D. as Chief Medical Officer and Javed Mahmood, D.D.S., Ph.D. as Senior Director of Clinical Development to lead its clinical pipeline.
Robert Sgroi was named Chief Commercial Officer to build the commercial organization ahead of potential launches for late-stage diagnostic programs JBS-002 & JBS-004.
JBS-003 (18F-fluoromisonidazole), a Phase 3 hypoxia tracer with FDA Breakthrough Therapy Designation, will be advanced by the new clinical team in trials for HPV-positive oropharyngeal carcinoma.
JBS-002 (Ga-68 PSMA PET kit for prostate cancer) & JBS-004 (F-18 PET agent for Alzheimer's disease) are advancing to registration batch manufacturing in the fourth quarter of 2026.
Dr. Behera brings 25 years of radiopharmaceutical experience, including leadership roles at Stanford University, Piramal Imaging, ImaginAb, & The Bracken Group.
Dr. Mahmood contributes over 20 years of oncology drug development experience, most recently serving as Director of Clinical Science at Moderna where he led trials for mRNA-4157.
Mr. Sgroi offers 30+ years of commercial leadership experience, having previously held executive roles at ITM, Jubilant Radiopharma, Piramal Imaging, & GE Healthcare.
Juniper intends to commercialize JBS-002 & JBS-004 if approved, with all commercial launches contingent upon FDA authorization.
The Company maintains three programs in registrational or Phase 3 development: JBS-003, JBS-002, & JBS-004.